Axsome director exercises 1,429 RSUs into shares
Axsome Therapeutics director Mark E. Saad reported routine equity compensation activity.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Axsome Therapeutics director Mark E. Saad reported routine equity compensation activity. On June 8, 2026, he exercised 1,429 restricted stock units (RSUs), which converted into 1,429 shares of common stock at a stated price of $0.0000 per share.
These RSUs were originally granted on June 6, 2025 and fully vested on their one-year anniversary. Following the conversion, Saad directly holds 11,431 shares of Axsome common stock. He also indirectly holds 300 shares as custodian for his children's UTMA accounts.
Insider Trade Summary
1,429 shares exercised/converted
Exercise
3 txns
Insider
Saad Mark E
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 1,429 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,429 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 0 contracts (Direct);
Common Stock — 11,431 shares (Direct);
Common Stock — 300 shares (Indirect, See Footnote.)
Footnotes (3)
- F1. On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant.
- F2. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- F3. Represents additional shares held indirectly by the Reporting Person prior to June 10, 2026, which includes shares indirectly beneficially owned by Mr. Saad as custodian for his children's UTMA accounts.
Key Figures
RSUs exercised: 1,429 units
Common shares from RSUs: 1,429 shares
Exercise price per share: $0.0000/share
+3 more
6 metrics
RSUs exercised
1,429 units
Restricted stock units converted to common stock on June 8, 2026
Common shares from RSUs
1,429 shares
RSUs convert into common stock on a one-for-one basis
Exercise price per share
$0.0000/share
Stated transaction price for RSU conversion
Direct holdings after transaction
11,431 shares
Total common stock directly owned after June 8, 2026 transaction
Indirect holdings
300 shares
Shares held as custodian for children's UTMA accounts
Derivative exercises
1 transaction, 1,429 shares
Exercise or conversion of derivative security (RSUs), code M
Key Terms
Restricted stock units ("RSUs"), derivative security, UTMA accounts
3 terms
Restricted stock units ("RSUs") financial
"Restricted stock units ("RSUs") convert into common stock on a one-for-one basis."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
UTMA accounts financial
"beneficially owned by Mr. Saad as custodian for his children's UTMA accounts."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Axsome Therapeutics (AXSM) disclose for Mark E. Saad?
Axsome Therapeutics reported that director Mark E. Saad exercised 1,429 restricted stock units, converting them into 1,429 shares of common stock. This was a routine equity compensation event, not an open-market purchase or sale, and reflects vested awards granted in June 2025.
What are the details of the 1,429 RSUs reported for Axsome (AXSM)?
The filing notes that 1,429 restricted stock units were granted on June 6, 2025, and fully vested on the one-year anniversary of that grant date. These RSUs converted into 1,429 shares of Axsome common stock on a one-for-one basis, consistent with the footnote explanation.
Was the Axsome (AXSM) Form 4 an open-market buy or sell?
No open-market buy or sell was reported. The key coded transaction was an “M” code, indicating exercise or conversion of a derivative security. The 1,429 RSUs converted into common shares as part of equity compensation rather than a discretionary market trade.
How are indirect Axsome (AXSM) holdings by Mark E. Saad described?
The Form 4 shows 300 shares of Axsome common stock held indirectly, labeled with a footnote. The footnote explains these shares are beneficially owned by Mr. Saad as custodian for his children's UTMA accounts, reflecting indirect, custodial ownership rather than direct personal holdings.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates